| European Federation of Internal Medicine

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News

Type: News Feed

PSUSA/00002558/202501

Submitted by Anonymous (not verified) on 2 December 2025 - 16:08

PSUSA/00002558/202501

Read more about PSUSA/00002558/202501

Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 November 2025, 14:00 (CET) to 18 November 2025, 15:00 (CET)

Submitted by Anonymous (not verified) on 2 December 2025 - 15:40

Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 November 2025, 14:00 (CET) to 18 November 2025, 15:00 (CET)

Read more about Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 November 2025, 14:00 (CET) to 18 November 2025, 15:00 (CET)

CAT quarterly highlights and approved ATMPs - December 2025

Submitted by Anonymous (not verified) on 2 December 2025 - 15:39

CAT quarterly highlights and approved ATMPs - December 2025

Read more about CAT quarterly highlights and approved ATMPs - December 2025

Opinion on medicine for use outside EU: Aluvia, lopinavir,ritonavir, HIV Infections, 21/09/2006 Positive opinion

Submitted by Anonymous (not verified) on 2 December 2025 - 15:17

Opinion on medicine for use outside EU: Aluvia, lopinavir,ritonavir, HIV Infections, 21/09/2006 Positive opinion

Read more about Opinion on medicine for use outside EU: Aluvia, lopinavir,ritonavir, HIV Infections, 21/09/2006 Positive opinion

Outcomes of imposed non-interventional post-authorisation safety studies

Submitted by Anonymous (not verified) on 2 December 2025 - 15:10

Outcomes of imposed non-interventional post-authorisation safety studies

Read more about Outcomes of imposed non-interventional post-authorisation safety studies

Human medicines European public assessment report (EPAR): Kaletra, lopinavir,ritonavir, Date of authorisation: 19/03/2001, Revision: 65, Status: Authorised

Submitted by Anonymous (not verified) on 2 December 2025 - 14:56

Human medicines European public assessment report (EPAR): Kaletra, lopinavir,ritonavir, Date of authorisation: 19/03/2001, Revision: 65, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Kaletra, lopinavir,ritonavir, Date of authorisation: 19/03/2001, Revision: 65, Status: Authorised

Human medicines European public assessment report (EPAR): Pregabalin Sandoz, pregabalin, Date of authorisation: 19/06/2015, Revision: 23, Status: Authorised

Submitted by Anonymous (not verified) on 2 December 2025 - 14:46

Human medicines European public assessment report (EPAR): Pregabalin Sandoz, pregabalin, Date of authorisation: 19/06/2015, Revision: 23, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Pregabalin Sandoz, pregabalin, Date of authorisation: 19/06/2015, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Izamby, denosumab, Date of authorisation: 26/06/2025, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 2 December 2025 - 14:45

Human medicines European public assessment report (EPAR): Izamby, denosumab, Date of authorisation: 26/06/2025, Revision: 2, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Izamby, denosumab, Date of authorisation: 26/06/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Mysildecard, sildenafil, Date of authorisation: 15/09/2016, Revision: 10, Status: Authorised

Submitted by Anonymous (not verified) on 2 December 2025 - 14:42

Human medicines European public assessment report (EPAR): Mysildecard, sildenafil, Date of authorisation: 15/09/2016, Revision: 10, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Mysildecard, sildenafil, Date of authorisation: 15/09/2016, Revision: 10, Status: Authorised

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

PSUSA/00002558/202501

Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 November 2025, 14:00 (CET) to 18 November 2025, 15:00 (CET)

CAT quarterly highlights and approved ATMPs - December 2025

Opinion on medicine for use outside EU: Aluvia, lopinavir,ritonavir, HIV Infections, 21/09/2006 Positive opinion

Outcomes of imposed non-interventional post-authorisation safety studies

Human medicines European public assessment report (EPAR): Kaletra, lopinavir,ritonavir, Date of authorisation: 19/03/2001, Revision: 65, Status: Authorised

Human medicines European public assessment report (EPAR): Pregabalin Sandoz, pregabalin, Date of authorisation: 19/06/2015, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Izamby, denosumab, Date of authorisation: 26/06/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Mysildecard, sildenafil, Date of authorisation: 15/09/2016, Revision: 10, Status: Authorised

Newsletters

Latest Newsletters

You are here

Newsletters

Latest Newsletters